AIDS
Conditions
Interventions
Experimental group:albuvirtide 320mg
Sponsors
The Second Hospital of Nanjing
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged > 18 years; 2. Start antiretroviral therapy within 6 months of HIV infection; 3. HIV RNA VL < 50 copies/mL (or below the detection limit) for at least 48 weeks; 4. HIV DNA VL < 150 copies/million PBMC; 5. No history of antiviral treatment failure, no treatment interruption, and no ibovirtine resistance.
Exclusion criteria
Exclusion criteria: 1. Combined with HBV or HCV infection; 2. Pregnancy or breastfeeding; 3. There are serious comorbidities or underlying diseases; 4. Those who are considered inappropriate by the investigator or who cannot complete the overall treatment course.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with plasma HIV RNA load< 50 copies/ml; | — |
Secondary
| Measure | Time frame |
|---|---|
| CD4+ T-cell count;Drug resistance to albuvirtide;Number of patients with adverse events of grade 3 or higher during treatment;Changes in HIV DNA levels in PBMCs; | — |
Countries
China
Contacts
Public ContactHu Zhiliang
The Second Hospital of Nanjing
Outcome results
None listed